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A fact well known to the readers of the Journal: heart disease is
the number 1 killer in our society, contributing to 600,000
deaths annually (1). Coronary heart disease (CHD) is respon-
sible for approximately two-thirds of these deaths, and 935,000
Americans experiencemyocardial infarction (MI) each year (1).
Hypertension, elevated low-density lipoprotein cholesterol
levels, smoking, and diabetes arewell appreciated as risk factors.
However, a particularly ominous risk for CHD arises in the
setting of chronic kidney disease (CKD) (2). As renal function
declines belowaglomerularﬁltration rate of 60ml/min/1.73m2,
the relative risk for cardiovascular mortality progressively
increases by 3-fold, as compared with those without CKD (3),
and almost 10-fold in the setting of CKD with diabetes (4).
Indeed, the cardiovascular risk conveyed by CKD exceeds that
conveyed by diabetes (5,6).
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The relationship between mineral metabolism and cardio-
vascular risk has been increasingly appreciated over the past 2
decades, now codiﬁed in the Kidney Disease: Improving
Global Outcomes (KDIGO) designation of CKD-MBD, for
“chronic kidney disease–mineral and bone disorder” (7). The
CKD-MBD designation only partially captures the clinical
implications; the underlying recognition that vascular calcium
deposition and skeletal bone mass are reciprocally and func-
tionally coupled inCKD is somewhat reﬂected in the “MBD,”
but the appellation does not fully capture the cardiovascular
risk associated with perturbation in this relationship. London
et al. (8) have nicely demonstrated that the presence and extent
of arterial intimal and medial calciﬁcation is a strong predictor
of cardiovascular mortality. The fortunate minority of those*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Diabetes and Obesity Research Center, Sanford-Burnham Medical
Research Institute at Lake Nona, Translational Research Institute at Florida Hospital,
Orlando, Florida. Dr. Towler is supported by National Institutes of Health grants
HL69229, HL81138, and HL114806 and by the Sanford-Burnham Medical
Research Institute; and serves on an advisory board for Merck & Co.with CKD on renal replacement therapy who do not exhibit
overt arterial calciﬁcation enjoy much greater longevity (8).
The elegant histomorphometric studies by London’s group
identiﬁed that dialysis patients with the most severe low-
turnover bone disease had the most extensive arterial
calcium load (9). Although hypercholesterolemia, hyperten-
sion, and hypercoagulability in CKD all certainly contribute,
coronary artery disease (CAD) morbidity and mortality
stubbornly persist in this high-risk population even when
aggressive therapeutic regimens targeting these risk factors are
implemented (10,11). Of note, the cardiovascular conse-
quences of perturbations in mineral metabolism (viz., phos-
phate and calcium metabolism) appear to be emerging in
patients with normal renal function as well. For example, at
every level of renal function, patients with type 2 diabetes
(T2DM) experience increased vascular calcium loads (12),
and CKD and T2DM synergistically enhance the risk forMI.
Moreover, serum calcium and phosphate levels portend all-
cause cardiovascular mortality at every level of renal function
(13). Thus, a role for calciotropic hormone signaling and
mineral metabolic in cardiovascular disease is increasingly
apparent. The prevailing metabolic and mechanical insults
that most frequently cause CKD (14) also promote cardio-
vascular calciﬁcation (15)ddisease that is worsened by
declining renal function that globally perturbs mineral
metabolism, including the bone–vascular axis (16). As such,
CKD represents ametabolic “perfect storm” for cardiovascular
disease.
In this issue of the Journal, Ferguson et al. (17) successfully
explore the enhanced CAD risk in the CRIC (Chronic Renal
Insufﬁciency Cohort) study to reveal novel insights into the
molecular genetics of cardiovascular disease. They implement
the working hypothesis that the high-risk milieu of CKD
would amplify the negative impact of genetic diathesis,
functioning as a metabolic magnifying glass to help identify
genes conveying CHD risk. As such, this strategy is some-
what, but imperfectly, analogous to the “sensitized screening”
used in genetic studies of lower eukaryotes (18). Coronary
artery calciﬁcation (CAC) scores obtained by multislice
computed tomography were used to quantify the aberrant
vascular mineral metabolism that demarcates and contributes
to arterial disease in the CRIC cohort. The ITMAT/Broad/
CARe (IBC) cardiometabolic single nucleotide poly-
morphism (SNP) array (Illumina, SanDiego, California) (19)
was then used to interrogate genetic variability at approxi-
mately 2,100 loci known to inﬂuence biologically plausible
and proven risk pathways in CHD. Because of the relatively
small CRIC cohort size (N ¼ 1,509), 2 other sets of CAC-
phenotyped patient populationsdthe PennCAC (Penn
Coronary Artery Calciﬁcation) study (N ¼ 2,560) and the
AFCS (Amish Family Calciﬁcation Study) (N¼ 784)dwere
used as independent “ﬁlters” to help further validate initial
ﬁndings from CRIC. Importantly, these latter groups were
not enriched for patients with CKD. This strategy helped
identify 23 gene loci that were correlated with CAC scores in
the CRIC and PennCAC cohort and/or the CRIC and
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800AFCS cohort. Importantly, chr9p21dthe premier locus
identiﬁed as conveying both CAC and CHD risk in genome-
wide association studies applied to the general population
(20)dwas identiﬁed by this methodology. Finally, to provide
robust evidence for the “hard”primary clinical endpoint ofMI,
these loci were used to interrogate the PROMIS (Pakistani
Risk of Myocardial Infarction Study) cohort. Following
this analysis, 4 locidchr9p21, COL4A1, ATP2B1, and
ABCA4dwere identiﬁed as contributing to MI risk. Both
chr9p21 and COL4A1 had been previously identiﬁed as
contributing to CAC scores in genome-wide association
studies (20). At this stage, even when correcting for multiple
comparisons (not done at earlier stages of discovery),ATP2B1
andCOL4A1 genetics signiﬁcantly portended increase risk for
MI in thePROMIS cohort lacking enrichment forCKD(17).
Why is this study so signiﬁcant? It is enlightening on
several levels. First, the impact of CKD speciﬁcally upon
CAC load before renal replacement therapy has needed
assessment in an adequately sized, well-phenotyped cohort,
and CRIC has provided this information (12,17). Moreover,
it conﬁrms and extends the association of chr9p21 and
COL4A1 genotype with coronary calcium load (17,20). Type
IV collagen is vital to basement membrane function and
vascular integrity, and alterations contribute to tissue calciﬁ-
cation risk in other venues (21,22). Indeed, type IV collagen
protein accumulation is more intense around sites of calciﬁ-
cation in patients with CKD (23). This suggests that addi-
tional research into the biological role of type IV collagen in
vascular calciﬁcation is warranted. Additionally, when viewed
in the context of other recent observations, this study suggests
that low-cost focused genotyping may yet provide important,
cost-effective risk stratiﬁcation in patients with equivocal
CAD risk. CAC arises primarily from atherosclerotic calci-
ﬁcation versus medial artery calciﬁcation (24), and for indi-
viduals at intermediate CHD risk by Framingham criteria,
CAC scoring helps better assess the probability for MI
(25,26). Thus, given these new results, genotyping for CAC
risk could be envisioned in an algorithm that augments the
implementation of computed tomography imaging to stratify
individual clinical CAD risk (27). Moreover, the loci identi-
ﬁed once again implicate mineral metabolism in the patho-
genesis of cardiovascular disease. The most intriguing
is ATP2B1, alias PMCA1. Via alternative splicing, this
gene encodes several different protein isoforms of plasma
membrane calciumATPase 1 (PMCA1), a plasmamembrane
ATPase that pumps cytosolic calcium across the membrane
and out of cells; via this action in vascular smooth muscle cells
(VSMCs), PMCA1 regulates vascular tone and blood pres-
sure (28). However, PMCA1 also plays global “house-
keeping” functions that are critical to cell viability, and it
would be interesting to knowwhether VSMC’s propensity for
apoptotic cell death (29) is altered by PMCA1 insufﬁciency
(30) is relevant to acute coronary events. Compensatory up-
regulation of VSMC PMCA4 with PMCA1 deﬁciency
may mitigate some of this risk. Moreover, PMCA1 also plays
a critical role in regulating bone-resorbing osteoclastactivation by receptor activator of nuclear factor kappa-B
ligand (RANKL) (31). This tumor necrosis factor super-
family member is not only necessary for osteoclast differen-
tiation, function, and survival (15,31), but is also implicated in
the pathobiology of vascular calciﬁcation (32). The ATP2B1
rs11105354A allele tracked both lower CAC score and blood
pressure, and it may be that global calcium homeostasis is also
altered in this genetic setting (17). Of note, the ATP2B1
rs11105354A allele was signiﬁcantly associated with
increased serum calcium levels (17). Finally, as the authors
point out (17), this type of sensitized screening (18) may be
useful in the identiﬁcation of new signaling pathways that
contribute to the pathogenesis of CAD through a focus on
atherosclerosis phenotypes in patients with CKD. It’s inter-
esting to note that the TLL1 genetic variant identiﬁed by
Cresci et al. (33) as signiﬁcantly associated with the extent of
CAD appears speciﬁc to the setting of T2DM; similar
examples of selective interactions between genotype, meta-
bolic milieu, and CAD risk may also arise in the setting of
CKD. Nevertheless, given the clinical management chal-
lenges we face with our increasingly aged and dysmetabolic
patient populationsdoften with concomitant reductions in
renal functiondthe insights afforded by genomics combined
withmultidisciplinary phenotyping of patients withCKDwill
no doubt provide novel strategies for assigning andmitigating
cardiovascular disease risk.
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